Abstracts tagged "Biomarkers"

Abstract Number: 2462 • ACR Convergence 2023
Mitochondrial-Mediated Neutrophil Activation in Dermatomyositis (DM) and Inclusion Body Myositis (IBM): Insights into Pathogenesis and Therapeutic Implications
Jorge Armando Gonzalez-Chapa¹, Jemima Albayda², Begum Horuluoglu³, Despina Michailidou¹, Marina Barguil Macedo¹, Lisa Christopher-Stine², Ingrid Lundberg⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Johns Hopkins University, Baltimore, MD, ³Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden
Background/Purpose: Dermatomyositis (DM) and inclusion body myositis (IBM) are characterized by muscle weakness and inflammation, with emerging evidence of mitochondrial and neutrophil involvement. Prior work…
Abstract Number: 0289 • ACR Convergence 2023
Markers of Endothelial Damage Are Elevated in Patients with Dermatomyositis Associated Interstitial Lung Disease and Associated with Low Paraoxonase-1 Activity
Sangmee Bae¹, Ani Shahbazian¹, Jennifer Wang², Tiffany De Leon¹, Yuna Lee¹, srinivasa Reddy³ and Christina Charles-Schoeman⁴, ¹UCLA Rheumatology, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³UCLA Department of Molecular and Medical Pharmacology, Los Angeles, CA, ⁴UCLA Medical Center, Santa Monica, CA
Background/Purpose: Damage to the vascular endothelium is implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM) and its associated interstitial lung disease (ILD), with microvascular…
Abstract Number: 0572 • ACR Convergence 2023
Serum/ Urine Levels and Expression of CD163 in Lupus Nephritis
Erdem Gurel¹, Suzan Cinar², Ozge Hurdogan³, Yasemin Ozluk³, Isin Kilicaslan⁴, Sibel Varelci¹, Safak Mirioglu⁵, Yasemin Yalcinkaya⁶, Ahmet Gul⁶, Lale Ocal¹, Murat Inanc⁶ and Bahar Artim-Esen⁶, ¹Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ²Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, ³Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁴Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbıl, Turkey, ⁵Division of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: CD163 is a glycosylated membrane protein expressed in monocytes and macrophages that phagocytize the hemoglobin/haptoglobin complex. As a result of proinflammatory stimuli, CD163 is…
Abstract Number: 0771 • ACR Convergence 2023
A Modified Idiopathic Pulmonary Fibrosis-Derived Composite Biomarker Score Is Associated with Interstitial Lung Disease Among U.S. Veterans with Rheumatoid Arthritis
Brent Luedders¹, Dana Ascherman², Daniel Kass³, Joshua Baker⁴, Michael Duryee¹, Yangyuna Yang¹, Punyasha Roul¹, K Wysham⁵, Paul Monach⁶, Andreas Reimold⁷, Gail Kerr⁸, Gary Kunkel⁹, Grant Cannon¹⁰, Jill Poole¹, Geoffrey Thiele¹, Ted R Mikuls¹¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵VA Puget Sound/University of Washington, Seattle, WA, ⁶VA Boston Healthcare System, Boston, MA, ⁷University of Texas Southwestern Medical Center, Dallas, TX, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹University of Utah, Salt Lake City, UT, ¹⁰University of Utah and Salt Lake City VA, Salt Lake City, UT, ¹¹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Based on the overlap in peripheral blood biomarkers associated with rheumatoid arthritis interstitial lung disease (RA-ILD) and idiopathic pulmonary fibrosis (IPF), a composite biomarker…
Abstract Number: 0938 • ACR Convergence 2023
Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum
Sunhwa Kim¹, Thierry Sornasse², Vishal Kakkar³, Rebecca Ross⁴, Yingtao Bi⁵, Hengcheng Hu², Lisa Hazelwood², Lauren Reinke-Breen⁶, jozsef karman⁷, Chris Butler², Jennifer Van Camp² and Francesco Del Galdo⁸, ¹AbbVie, Inc., South San Francisco, CA, ²AbbVie, Inc., North Chicago, IL, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁵AbbVie, Inc., Worcester, MA, ⁶AbbVie, Inc., Vernon Hills, IL, ⁷AbbVie, Inc., San Francisco, CA, ⁸University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease that affects multiple organs asynchronously, leading to highly variable fibrotic damage and consequent increased morbidity and mortality.…
Abstract Number: 1282 • ACR Convergence 2023
Proteomic Signature in Peripheral Blood and Sputum in Rheumatoid Arthritis Patients with and Without Lung Involvement
Meliha Kapetanovic¹, Olivia Olsson², Jon Einarsson¹, Morteza Najibi³ and Ellen Tufvesson⁴, ¹Lund University and Skåne University Hospital, Lund, Sweden, ²Lund University, Faculty of Medicine, Lund, Sweden, ³Lund University, Institution for clinical sciences, section for rheumatology Lund, Lund, Sweden, ⁴Lund University, Institution for clinical scienses, section for lung medicine and allergy, Lund, Sweden
Background/Purpose: Rheumatoid arthritis (RA) related lung manifestations have a significantly impact the morbidity and mortality. Male gender and RF/ACPA positivity are known risk factors but…
Abstract Number: 1625 • ACR Convergence 2023
Identifying Potential Neuroimaging Biomarkers of Neuropsychiatric Lupus in Children Using Deep Learning
santiago arciniegas¹, Matthias W. Wagner², Logi Vidarsson², Birgit Ertl-Wagner², Tala El Tal³, Asha Jeyanathan², Lawrence Ng², Linda Hiraki², Deborah Levy², George M. Ibrahim² and Andrea Knight², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Childhood-onset SLE (cSLE) is characterised by a higher frequency of nervous system involvement, known…
Abstract Number: 1763 • ACR Convergence 2023
Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up
Drayton Rorah¹, Linh Ngo², Mario Castro², Kristen Demoruelle³ and Scott Matson⁴, ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas School of Medicine, Kansas City, KS, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Kansas School of Medicine, Kansas City, MO
Background/Purpose: The lung airways have been implicated in the pathogenesis of RA. RA-associated autoantibodies, including anti-cyclic citrullinated peptide (anti-CCP) antibodies are found to be generated…
Abstract Number: 2176 • ACR Convergence 2023
Cellular and Proteomic Changes Following Administration of Peresolimab, in a Phase 2a Trial in Rheumatoid Arthritis
Robert J. Benschop¹, Jay Tuttle¹, Paul Emery², Christoph Preuss¹, Mark Daniels¹, Veavi Ching-Yun Chan¹, Pia Yachi¹ and Ajay Nirula¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). Peresolimab demonstrated superiority to placebo in Disease…
Abstract Number: 2353 • ACR Convergence 2023
Role of Insulin-like Growth Factor Binding Protein-7 (IGFBP7) in Pulmonary Hypertension Pathogenesis and as a Biomarker Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Ye Jin Jeong¹, Soumyaroop Bhattacharya¹, Maria de la Luz Garcia-Hernandez², Javier Rangel-Moreno¹, Qingfu Xu³ and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²University of Rochester, West Henrietta, NY, ³CanSino Biologic Inc., Tianjin, China
Background/Purpose: Systemic sclerosis (SSc, scleroderma) is an autoimmune connective tissue disease that causes autoimmunity, vascular dysfunction, and fibrosis of the skin, lungs, and other organs.…
Abstract Number: 2483 • ACR Convergence 2023
CD68 and Fibrinoid Necrosis Are Synovial Biomarkers of Severity in Early Rheumatoid Arthritis and Are Associated with a Better Response to Methotrexate: Analysis of the UCLouvain Brussels ERA Cohort
Francesco Natalucci¹, clement triaille², Emilie Sapart², Cécile VAN MULLEM², Tatiana Sokolova³, Laurent MERIC de BELLEFON², Adrien NZEUSSEU TOUKAP², Christine GALANT⁴, Bernard Lauwerys⁵ and Patrick Durez², ¹UCLouvain University, Sermoneta, Italy, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ³Université Catholique de Louvain, Brussels, Belgium, ⁴Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain), Anatomie pathologique, Brussels, Belgium, ⁵UCB Pharma, Brussels, Belgium
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with persistent synovial inflammation. Despite early diagnosis and the treatment-to-target strategy in ERA, the treatment response…
Abstract Number: 0020 • ACR Convergence 2023
The Inflammatory Proteome in Sjögren’s Syndrome Identifies New Biomarkers and Relevant Clinical Subgroups
José Miguel Sequí-Sabater¹, Carlos Perez-Sanchez², Clarissa Meoni³, Tomás Cerdó-Ráez⁴, Maria del Carmen Abalos-Aguilera⁵, Desiree Ruiz Vilchez⁵, Francisco Cepas⁴, Nuria Barbarroja⁶, Alejandro Escudero⁷, Mª Angeles Aguirre⁸, Chary Lopez-Pedrera⁹ and Lorenzo Beretta¹⁰, ¹Agencia Valenciana de Salut/ Hospital Universitari de la Ribera/ Unitat de Reumatología, Gandía, Spain, ²IMIBIC, Córdoba, Spain, ³Ospedale Policlinico di Milano, Milan, Italy, ⁴Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ⁵Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁶University of Cordoba, Córdoba, Spain, ⁷SAS, Córdoba, Spain, ⁸Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁹IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ¹⁰Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Italy
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterised by glandular involvement of the eye and salivary glands, leading to xerostomia and xerophthalmia. In…
Abstract Number: 0366 • ACR Convergence 2023
Active Joint Acoustic Emissions on the Achilles Tendon: A Digital Biomarker of Enthesitis Related Arthritis
Quentin Goossens¹, Miguel Locsin², Emily Moise³, Lori Ponder⁴, Omer Inan¹ and Sampath Prahalad⁵, ¹Georgia Institute of Technology, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Georgia Institute of Technolgy, Atlanta, GA, ⁴Children's Healthcare of Atlanta, Atlanta, GA, ⁵Emory University School of Medicine, Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a chronic condition in children that causes joint inflammation. Enthesitis-related arthritis (ERA), a subtype of JIA, affects 10-20% of…
Abstract Number: 0575 • ACR Convergence 2023
The Real-World Utility of a Lupus Activity Monitoring Panel in the United States Community Rheumatologist Practice
Andrew Concoff¹, Laura Moore-Schiltz², Vijay Nadipelli³, Tyler O'Malley¹, Karen Worley⁴, Allison Petrilla², Debra Zach¹, Scott B. Robinson², Sara Taiyari⁵, Barton Jones² and Bernard Rubin⁶, ¹Exagen, Vista, CA, ²Inovalon, Bowie, MD, ³GlaxoSmithKline, Philadelphia, PA, ⁴GlaxoSmithKline, US Value Evidence and Outcomes, Cincinnati, OH, ⁵GlaxoSmithKline, Collegeville, PA, ⁶GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC
Background/Purpose: Patients with active SLE have periods of uncontrolled disease activity that are associated with a greater risk for developing irreversible organ damage. Current standard…
Abstract Number: 0780 • ACR Convergence 2023
Assessing Differential Effects of DMARDs on Psoriasis Area and Severity Index and Patient Global Assessment in Subgroups of Patients with Active PsA Treated over 52-weeks with Secukinumab in a Non-Interventional Trial (AQUILA) Using a Multistage Clustering Approach
Michaela Koehm¹, Maximilian Klippstein², Sabine Kugler³, Sina Mackay³, Daniel Schulz³, Asmir Vodencarevic⁴, Guillaume Wendt⁴, Daniel Peterlik⁴, Uta Kiltz⁵, Jan Brandt-Juergens⁶ and Frank Behrens⁷, ¹University Hospital Frankfurt, Frankfurt, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Frankfurt, Germany, ³Fraunhofer Institute for Intelligent Analysis and Information Systems IAIS, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Sankt Augustin, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Individualized treatment strategies are of high importance in the treatment of patients with active psoriatic arthritis (PsA), a heterogeneous immune-mediated disease. IL-17 inhibition has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].